NASDAQ:BGM - Nasdaq - KYG7307E1237 - Common Stock - Currency: USD
Taking everything into account, BGM scores 3 out of 10 in our fundamental rating. BGM was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for BGM as it has an excellent financial health rating, but there are worries on the profitability. BGM is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -2.72% | ||
ROE | -3.38% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 16.39% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 105.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.39 | ||
Quick Ratio | 2.82 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 2602.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:BGM (7/25/2025, 11:15:19 AM)
10.36
-0.59 (-5.39%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 67.06 | ||
P/FCF | N/A | ||
P/OCF | 3092.77 | ||
P/B | 39.38 | ||
P/tB | 44.05 | ||
EV/EBITDA | 2602.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -2.72% | ||
ROE | -3.38% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 16.39% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 106.56% | ||
Cap/Sales | 5.25% | ||
Interest Coverage | N/A | ||
Cash Conversion | 80.81% | ||
Profit Quality | N/A | ||
Current Ratio | 3.39 | ||
Quick Ratio | 2.82 | ||
Altman-Z | 105.15 |